


solianis monitoring ag

Innovative, Proprietary Technology

Various non-invasive devices under development have shown promising results in measuring glucose levels under controlled conditions, but failed to succeed in daily life. Solianis' proprietary, patented technology is unique in that it uses a multi-sensor concept to address the influence of perturbing factors such as


- body temperature,
- microcirculation,
- sweat,
- Moisture in the skin and
- the thickness of different skin layers.

It thereby allows for a more reliable monitoring of changes in glucose levels in daily life.




Unmet Need in Diabetes Management

Traditional finger-stick devices only provide single-point-in-time measurements and miss potentially critical hypo- and hyperglycaemic events leading to severe complications. Furthermore, the pain associated with the testing impairs patient compliance. This has led to the development of Continuous Glucose Monitoring (CGM) which allows to achieve tight glycemic control and thereby improve the quality of life. Currently, there are minimal-invasive devices on the market, but the patients still wait for a truly non-invasive device.



Positive Clinical Trial Results

In a series of clinical trials conducted at the University Hospital Zurich since May 2006, Solianis has tested the effectiveness of its technology. Compared to minimally invasive devices that are on the market, our clinical results are promising and with the improvements planned for hardware, software, attachment and sensor design a future device will provide valuable information to the patient.



Validation of point accuracy, compared to the results of a minimally invasive device (Dexcom STS):

	A+B	C	D	E
Solianis	96.1%	1.19%	2.72%	0%
Dexcom	97.54%	0%	1.76%	0%

Strong Intellectual Property

Solianis has one issued patent, one patent accepted for allowance in the US and six filed patent applications covering the multi-sensor platform concept for continuous glucose monitoring, thus creating a barrier to entry for competitors. It is pursuing an aggressive strategy to continuously adding additional patent applications to protect its innovative multi-sensor platform.

Experienced Management and R&D Expertise

Solianis has assembled an experienced management team at Solianis and Board of Directors who are experts in commercializing novel medical devices and creating value for patients and shareholders. Its high-quality Scientific Advisory Board includes leading physicians and researchers from Germany, Israel, the UK and Switzerland.

Contact

Solianis Monitoring AG
 Leutschenbachstrasse 46
 8050 Zürich Switzerland
 Tel +41 44 306 80 40
 Fax +41 44 306 80 41
 www.solianis.com